Avectas cofounder and chief executive Dr Michael Maguire, with cofounder Dr Shirley O’Dea, chief scientific officer and business development director Dr Gillian Hendy. Photograph: Iain White/Fennells

Serial entrepreneur Seamus Mulligan has led a $10 million (€12 million) fundraising for an Irish business at the cutting edge of cell therapy. Avect(...)

Two members of the Manchester fire department in New Hampshire assess the condition of a man who had overdosed on heroin and who was revived with two doses of Narcan. Photograph: Don Emmert/AFP/Getty Images

In hindsight, it looks like a no-brainer. Take a tried and tested drug that addresses a burgeoning epidemic and make it easier to use. Then sit back a(...)

An overdose rescue kit featuring nasal spray and injectable Naloxone at a demonstration in New York. File photograph: Getty Images

Six Irish businessmen will share a $635 million (€542m) payday after selling a company that developed a drug used in the frontline as the United State(...)

Profector’s patent-protected electrospraying and electrospinning technology is aimed at research scientists in academic institutions, life sciences companies and government agencies

  Adapt Pharma, the latest venture of serial pharmaceuticals entrepreneur Séamus Mulligan, has invested in a high-tech medical devices bus(...)

Séamus Mulligan  co-founded Dublin-based Adapt with fellow serial pharmaceutical entrepreneurs David Brabazon and Eunan Maguire

Entrepreneur Séamus Mulligan has cashed in shares worth $86 million (€62 million) in Jazz Pharmaceuticals which will entirely be used to fund a new(...)

Trials are starting initially in Australia as the regulatory path there was considered quicker to negotiate, according to the company’s Australian chief executive, Peter Crosby.

It has taken three years to get a product to trials: Mainstay Medical hopes that within another two, it will have a device on the market in Eur(...)

“The results are, for us at least, pretty exciting. They show that the therapy that’s delivered by our product appears to work and the results have certainly captured the attention of the clinical community with which we work,” said Mainstay chief executive Peter Crosby.

Mainstay Medical, an Irish medtech company targeting chronic lower back pain, is starting clinical trials on its Reactiv8 implantable device. (...)